BioMarin reports FDA approves expanded indication for Voxzogo

BioMarin Pharmaceutical announced that the U.S. Food and Drug Administration has approved the supplemental New Drug Application, or sNDA, for Voxzogo to increase linear growth in pediatric patients with achondroplasia with open epiphyses, or growth plates. This indication is approved under accelerated approval based on an improvement in annualized growth velocity. Previously, Voxzogo was indicated for children who were 5 years of age and older. This expanded indication now includes children of all ages with open growth plates, the company noted.